Loading market dashboard
Mesoblast Limited
MESOHealthcareNASDAQAU
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Achieved Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Activity Report for Quarter Ended March 31, 2026 (Appendix 4C) NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX: MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the third fiscal quarter ended March 31, 2026.
Achieved Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Activity Report for Quarter Ended March 31, 2026 (Appendix 4C) NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the third fiscal quarter ended March 31, 2026. “We've had a busy and exciting March quarter marked by a series of major achievements.
NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that its pivotal Phase 3 clinical trial evaluating rexlemestrocel-L for the treatment of chronic low back pain (CLBP) associated with degenerative disc disease has achieved its patient recruitment target. This marks a significant milestone in Mesoblast's plans for commercialization of rexlemestrocel-L, its proprietary allogeneic stromal cell therapy targeting inflammatory processes underlying disc degeneration.
NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has acquired an exclusive worldwide license to a patented chimeric antigen receptor (CAR) technology platform for precision-enhanced augmentation of therapeutic mesenchymal lineage stromal cell (MSC) products. Mesoblast plans to incorporate the engineered CARs to further boost effectiveness of Mesoblast's products, with the goal of enhancing the target specificity and augmenting inherent properties of immunomodulation and tissue regeneration.
Stock News JPMorgan tops Q1 estimates: JPMorgan Chase (JPM) posted Q1 EPS of $5.94 on revenue of $50.54B, beating estimates on stronger fixed income trading and
Mesoblast Limited (NASDAQ: MESO - Get Free Report) Director Gregory George bought 1,981,890 shares of Mesoblast stock in a transaction that occurred on Thursday, April 9th. The stock was purchased at an average cost of $8.59 per share, with a total value of $17,024,435.10. Following the completion of the transaction, the director owned 13,586,890 shares of
Mesoblast Limited (NASDAQ: MESO - Get Free Report) Director Gregory George acquired 4,000,000 shares of the business's stock in a transaction on Saturday, April 4th. The stock was acquired at an average cost of $1.42 per share, for a total transaction of $5,680,000.00. Following the transaction, the director owned 12,000,000 shares of the company's stock, valued
Mesoblast Limited (NASDAQ: MESO - Get Free Report) Director Gregory George acquired 2,324,072 shares of the stock in a transaction dated Friday, April 10th. The shares were purchased at an average price of $1.48 per share, for a total transaction of $3,439,626.56. Following the completion of the purchase, the director directly owned 8,324,072 shares in the
Working with Parent Project Muscular Dystrophy and the Duchenne Registry on patient identification and trial awareness efforts
Mesoblast Limited (MESO) Discusses Cellular Medicine Platforms and Innovations at R&D Day Transcript
Mesoblast (MESO) is upgraded to a speculative Buy as Ryoncil outperforms in pediatric SR-aGVHD and advances rapidly into a registrational DMD trial. Ryoncil's DMD opportunity is underappreciated, with a modeled $2B peak sales and $1.18B risk-adjusted NPV, enabled by FDA confidence in its safety profile. SR-aGVHD remains a niche but high-margin market, with Ryoncil nearing $100M in sales and strong launch adoption, though adult expansion faces competition.
Mesoblast outlines commercial strategy to double net revenues as Ryoncil ® approaches US$100M net revenue milestone since launch last year
Partnering with Parent Project Muscular Dystrophy to ensure timely access to the trial for eligible patients ~15,000 children are living with DMD in the U.S. NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance to directly proceed for a registrational clinical trial evaluating Ryoncil® (remestemcel-L-rknd) in Duchenne muscular dystrophy (DMD), which affects approximately 15,000 children in the U.S.1 Ryoncil® is the first mesenchymal stromal cell (MSC) product approved by FDA, and the only product approved for children under age 12 with steroid-refractory acute graft-versus-host disease (SR-aGvHD)2. This new registrational trial builds on Ryoncil's® proven safety in children, evidence of efficacy in DMD preclinical models, and FDA-approved manufacturing process.
Strong growth in February/March following January seasonality Net revenue approaches US$100M since launch NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced Ryoncil® (remestemcel-L-rknd) net sales were US$30.3 million for the quarter ended March 31, 2026.1 Strong sales in February and March offset holiday seasonality in January. Revenue generated during this first year of Ryoncil® launch approaches US$100 million.
NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host its inaugural R&D Day on Wednesday, April 8, 2026 in New York City. The event will be webcast live from 8:00am to 11:00am EST and will include presentations from Mesoblast's senior leadership team and from key opinion leaders.
NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the appointment of Teresa Montagut MD, PhD in the newly established position of Head of Clinical Development and Medical Affairs reporting to the Chief Medical Officer Dr. Eric Rose. In this role, Teresa will lead Mesoblast's medical affairs organization, fostering clinical collaborations and spearheading investigator-initiated trials, enhancing clinical and medical communications, and engaging with healthcare professionals. She will play a critical role in unlocking the value of Mesoblast's cell therapy programs in new pediatric and adult inflammatory conditions in partnership with investigators and key opinion leaders.
